|
Daily Medical Update
Warts and Benign Skin Lesions
Wednesday, August 12, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Medicine (2026) - Systematic Review and Network Meta-Analysis
Key Findings
- Intralesional saline had the highest probability of being the best treatment for complete response (96%) and partial response (98%) in the network analysis.
- No statistically significant differences were found among treatment arms for most comparisons; blister formation was more frequent with cryotherapy (P = .03) and Mycobacterium w vaccine (P = .02).
📋 Practice Implication: Use the pooled ranking cautiously when choosing intralesional therapy, because the apparent saline advantage and limited between-treatment differences do not establish a definitive preferred regimen.
|
Journal of cosmetic dermatology (2026) - Randomized Controlled Trial
Key Findings
- Wart number, thickness, and diameter decreased in both groups, with significantly greater reductions after intralesional interferon alfa-2b than after cryotherapy.
- Post-treatment CD3+, CD4+, CD4+/CD8+, IL-2, IL-6, IgE, and IFN-γ levels increased more and CD8+ levels decreased more with interferon than with cryotherapy; Dermatology Life Quality Index scores were also lower.
📋 Practice Implication: Intralesional interferon alfa-2b is a reasonable alternative for hand or foot warts when a larger lesion and quality-of-life response is prioritized over standard cryotherapy.
|
Journal of the American Academy of Dermatology (2025) - Randomized Controlled Trial
Key Findings
- Complete cure rates were similar with intralesional acyclovir and cryotherapy: 68.6% versus 61.1% (P = .393).
- Acyclovir required more sessions to achieve complete cure (3.8 versus 3; P = .001) and caused greater procedural pain (visual analog scale 6.5 versus 4.65; P = .005).
📋 Practice Implication: For plantar warts, cryotherapy remains the more convenient first choice when efficacy is comparable and minimizing treatment burden and procedural pain matters.
|
Indian journal of dermatology, venereology and leprology (2026) - Randomized Clinical Trial
Key Findings
- Complete response was higher with intralesional MMR than vitamin D3 (80.4% versus 66.1%).
- Both groups averaged four treatment sessions, while mild pain (96.4%) and injection-site itching (12.5%) were more common with MMR; six-month recurrence was 3.6% with MMR versus 5.4% with vitamin D3.
📋 Practice Implication: MMR can be favored over vitamin D3 for multiple warts when maximizing initial clearance is the main goal and mild injection-related effects are acceptable.
|
Journal of cosmetic dermatology (2026) - Systematic Review and Meta-Analysis
Key Findings
- Vitamin D3 produced lower complete clearance than MMR (risk ratio 0.85; 95% CI 0.75-0.96; P = .01) and more no-response outcomes (risk ratio 2.40; 95% CI 1.40-4.13; P = .002).
- Recurrence and pain did not differ significantly, while vitamin D3 caused more swelling (risk ratio 2.79; 95% CI 1.15-6.75) and MMR was associated with more erythema.
📋 Practice Implication: The pooled evidence supports selecting MMR over vitamin D3 for nongenital warts when clearance is the priority, while counseling patients that the adverse-event profiles differ rather than uniformly favoring one agent.
|
|
💡
Summary
Recent evidence favors intralesional immunotherapy as an option for persistent cutaneous warts, but comparative results vary by agent and outcome. Interferon alfa-2b and MMR produced greater lesion reduction or clearance than their comparators in randomized studies, whereas acyclovir had similar efficacy to cryotherapy with more pain and treatment sessions; a network meta-analysis also found substantial uncertainty across modalities.
|
|